This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

ERNEST Q. KING, M.D.; CHARLES N. LEWIS, M.D.; HENRY WELCH, Ph.D.; EUGENE A. CLARK, Jr., M.D.; JOHN B. JOHNSON, M.D.; JOHN B. LYONS, M.D.; ROLAND B. SCOTT, M.D.; PAUL B. CORNELY, M.D.

J Am Med Assoc. 1950;143(1):1-4.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The discovery of a new antibiotic called terramycin was reported recently by Finlay and associates.¹ This drug is produced by Streptomyces rimosus, a new actinomycete isolated from a soil sample, and is described as a crystalline amphoteric substance which can form either salts with acids (terramycin hydrochloride) or salts with bases (the sodium salt of terramycin). Currently, 1 microgram of the amphoteric compound has been defined as containing 1 microgram of activity, and the activity of the salts are stated in terms of the equivalent weight of pure terramycin. In vitro the antibiotic has a wide activity against many species of bacteria, both gram positive and gram negative.² The purpose of this preliminary study is to report the clinical results observed after the oral administration of terramycin hydrochloride³ in patients with various infections, which are described in the accompanying table.

From the tabulation it will be noted . . . [Full Text PDF of this Article]

Author Affiliations
Washington, D. C.

From the Federal Security Agency, Food and Drug Administration (Drs. King, Lewis and Welch) and Freedmen's Hospital (Dr. Clark, Johnson, Lyons, Scott and Comely).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?